S6E19 Stuart Grant | MedTech Innovation

Being an Engineer · 9 May 2025 · 51m · Episode 19

What this episode covers

Dr. Stuart Grant, founder of Archetype MedTech, discusses his 25-year career at Johnson & Johnson and DePuy Synthes before launching his consultancy to help startups navigate medical device development. He details the challenges of securing funding, managing regulatory differences between the EU's MDR and the US FDA, and the strategic importance of narrow clinical indications. Grant also explores future trends in surgical robotics and AI, emphasizing the need for modular platforms and the value of accumulated engineering knowledge.

Other shows on the same ground, closest first.

  • Global Medical Device Podcast · 39m

    #455: MedTech Founder 101: Shifting from Corporate to Startup with John Schindler

    John Schindler, CEO of Liquet Medical, discusses the transition from corporate roles at Atrium and Merit Medical to founding a startup, emphasizing the 'novel but simple' philosophy for vascular drug delivery devices. He explains how Liquet leverages its 510(k) clearance for pulmonary embolism treatment while planning an IDE trial, advocating for limited market releases to build strategic enterprise value through intentional clinical data. Schindler also covers the challenges of fundraising, negotiating with regulatory service providers, and the importance of early FDA engagement to avoid timeline resets.

  • Global Medical Device Podcast · 32m

    Understanding the Value of a Medical Device Guru

    Tom Rish, Senior Medical Device Guru and manager of the Guru team at Greenlight Guru, explains how the company provides mentorship and regulatory support to medical device companies beyond its QMS software. He discusses the 'Guru Edge,' emphasizing a phased 'build as you go' approach to quality systems to help startups launch products and pass audits without being overwhelmed by paperwork. Rish highlights industry trends including the rise of wearables, software as a medical device (SaMD), and the impact of EU MDR and IVDR regulations on In Vitro Diagnostics (IVD).

  • Global Medical Device Podcast · 35m

    #391: Creating a Regulatory Roadmap for MedTech Market Success with Adnan Ashfaq

    Adnan Ashfaq, founder of SimplyMedica, explains how to create a regulatory roadmap to guide medical device companies through market access and secure investor confidence. He distinguishes the roadmap from a regulatory strategy, detailing its role in outlining costs, timelines, and regional requirements for markets like the US, EU, and Japan. Ashfaq emphasizes that precise language in intended use statements and accurate device classification are critical to avoiding costly missteps and leveraging strategic opportunities, such as entering the UK market before regulatory tightening.

  • Global Medical Device Podcast · 49m

    Pros & Cons of Being a Physician turned MedTech Inventor

    Dr. Amy Baxter, CEO and founder of Pain Care Labs, discusses her journey from emergency physician to MedTech inventor, detailing the creation of Buzzy® and VibraCool® devices to manage pain without opioids. She explains how her clinical observations led to combining cold therapy with mechanical stimulation, navigating the rigorous ISO 13485 regulatory process and securing NIH SBIR funding to bring the products to market. Baxter advises physician inventors to fall in love with the problem rather than the solution, emphasizing the importance of understanding regulatory pathways, branding, and avoiding unnecessary NDAs. The episode highlights the specific challenges of developing pain management devices, including subjective efficacy metrics and the long timeline from prototype to commercial launch.

  • Global Medical Device Podcast · 40m

    Challenges for Regulatory Submission: EU vs. US

    Michelle Lott, Founder of leanRAQA and former FDA DGMPAC member, explains the severe regulatory hurdles of the EU MDR compared to the US FDA pathway, noting that 18,000 MDD certificates were issued but only 1% have transitioned to MDR. She highlights that companies face exorbitant notified body fees, a bottleneck of only 28 notified bodies, and the requirement for ISO 13485 certification, leading many small and large firms to withdraw from the EU market. Lott advises startups to perform a market analysis to determine if their revenue model supports these recurring costs, warning that 'hope is not a regulatory strategy' as certificates expire in May 2024. The discussion covers the shift from a linear US submission process to a continuous, living system in the EU, including annual audits and recertification every three years.

The summary, chapters and topics are generated from the episode’s audio by this directory, not written by Being an Engineer. The episode itself belongs to its publisher.